NasdaqGS:MEDPLife Sciences
Medpace Lawsuits And CEO Sales Test Growth Story And Valuation
Medpace Holdings (NasdaqGS:MEDP) is facing multiple shareholder class action lawsuits tied to alleged false and misleading statements about its book to bill ratio and backlog cancellation rates.
Investors claim they suffered losses after company disclosures, with recent insider stock sales by the CEO shortly before negative updates adding to concerns.
The litigation focuses on whether management provided overly optimistic projections that did not align with internal business conditions.
For...